Wuji wan formula ameliorates diarrhea and disordered colonic motility in post-inflammation irritable bowel syndrome rats by modulating the gut microbiota

Frontiers in Microbiology

Volumn 8, Issue NOV, 2017, Pages

  Chen, Ying ^a   Xiao, Shuiming ^a   Gong, Zipeng ^b   Zhu, Xiaoxin ^a   Yang, Qing ^a   Li, Yujie ^a   Gao, Shuangrong ^a   Dong, Yu ^a   Shi, Zhe ^a   Wang, Yajie ^a   Weng, Xiaogang ^a   Li, Qi ^a   Cai, Weiyan ^a   Qiang, Weijie ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Gut microbiota; Mucin; Post inflammation irritable bowel syndrome; Tight junctions; Wuji Wan

Indexed keywords

CHINESE DRUG; COPTIS RHIZOME EXTRACT; ENEMA; EVODIA FRUIT EXTRACT; MUCIN 2; MYOSIN LIGHT CHAIN KINASE ISOENZYME; OCCLUDIN; PINAVERIUM BROMIDE; PLANT EXTRACT; PROTEIN ZO1; RADIX PAEONIAE ALBA EXTRACT; UNCLASSIFIED DRUG; WATER; WUJI WAN;

ABDOMINAL PAIN; AKKERMANSIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEROIDES; BODY WEIGHT; CELL PROLIFERATION; COLON MOTILITY; COLON MUCOSA; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DOWN REGULATION; FECES MICROFLORA; FEMALE; GENE EXPRESSION PROFILING; GOBLET CELL; HYPERSENSITIVITY; IMMUNOFLUORESCENCE TEST; INTESTINAL DYSMOTILITY; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; NONHUMAN; PARASUTTERELLA; POLYMERASE CHAIN REACTION; PREVOTELLA; PROTEIN EXPRESSION; RAT; SPECIES RICHNESS; TAXONOMY; UPREGULATION; VISCERA; VISCERAL HYPERSENSITIVITY; WATER CONTENT;

EID: 85035033188     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2017.02307     Document Type: Article

References (47)

1. Acosta, A., Camilleri, M., Shin, A., Nord, S. L., O'Neill, J., Gray, A. V., et al. (2016). Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. Clin. Transl. Gastroenterol. 7, e173. doi: 10.1038/ctg.2016.32
2. Axling, U., Olsson, C., Jie, X., Fernandez, C., Larsson, S., Ström, K., et al. (2012). Green tea powder and Lactobacillus plantarum affect gut microbiota, lipid metabolism and inflammation in high-fat fed C57BL/6J mice. Nutr. Metab. 9:105. doi: 10.1186/1743-7075-9-105
3. Baldwin, J., Collins, B., Wolf, P. G., Martinez, K., Shen, W., Chuang, C. C., et al. (2015). Table grape consumption reduces adiposity and markers of hepatic lipogenesis and alters gut microbiota in butter fat-fed mice. J. Nutr. Biochem. 27, 123-135. doi: 10.1016/j.jnutbio.2015.08.027
4. Bennet, S. M. P., öhman, L., and Simrén, M. (2015). Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver 9, 318-331. doi: 10.5009/gnl14344
5. Carroll, I. M., Chang, Y. H., Park, J., Sartor, R. B., and Ringel, Y. (2010). Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog. 2:19. doi: 10.1186/1757-4749-2-19
6. Chen, Y., Li, Y., Wang, Y., Yang, Q., Yu, D., Weng, X., et al. (2015). Comparative pharmacokinetics of active alkaloids after oral administration of Rhizoma coptidis extract and Wuji Wan formulas in rat using a UPLC-MS/MS method. Eur. J. Drug Metab. Pharmacokinet. 40, 67-74. doi: 10.1007/s13318-014-0181-1
7. Chey, W. D. (2016). Food: the main course to wellness and illness in patients with irritable bowel syndrome. Am. J. Gastroenterol. 111, 366-371. doi: 10.1038/ajg.2016.12
8. Codling, C., O'Mahony, L., Shanahan, F., Quigley, E. M. M., and Marchesi, J. R. (2010). A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig. Dis. Sci. 55, 392-397. doi: 10.1007/s10620-009-0934-x
9. Dai, C., Guandalini, S., Zhao, D. H., and Jiang, M. (2012). Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function. Mol. Cell. Biochem. 362, 43-53. doi: 10.1007/s11010-011-1126-5
10. Dennis, K. L., Wang, Y., Blatner, N. R., Wang, S., Saadalla, A., Trudeau, E., et al. (2013). Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. Cancer Res. 73, 5905-5913. doi: 10.1158/0008-5472.CAN-13-1511
11. Derrien, M., Vaughan, E. E., Plugge, C. M., and Vos, W. M. D. (2004). Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int. J. Syst. Evol. Microbiol. 54(Pt 5), 1469-1476. doi: 10.1099/ijs.0.02873-0
12. El-Salhy, M. (2012). Irritable bowel syndrome: diagnosis and pathogenesis. World J. Gastroenterol. 18, 5151-5163. doi: 10.3748/wjg.v18.i37.5151
13. Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., et al. (2013). Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. U.S.A. 22110, 9066-9071. doi: 10.1073/pnas.1219451110
14. Everard, A., Lazarevic, V., Derrien, M., Girard, M., Muccioli, G., Neyrinck, A., et al. (2011). Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60, 2775-2786. doi: 10.2337/db11-0227
15. Fazal, F., Gu, L., Ihnatovych, I., Han, Y., Hu, W., Antic, N., et al. (2005). Inhibiting myosin light chain kinase induces apoptosis in vitro and in vivo. Mol. Cell. Biol. 25, 6259-6266. doi: 10.1128/MCB.25.14.6259-6266.2005
16. Gong, Z., Chen, Y., Zhang, R., Wang, Y., Guo, Y., Yang, Q., et al. (2014). Pharmacokinetic comparison of berberine in rat plasma after oral administration of berberine hydrochloride in normal and post inflammation irritable bowel syndrome rats. Int. J. Mol. Sci. 15, 456-467. doi: 10.3390/ijms15010456
17. Han, K., Wang, J., Seo, J. G., and Kim, H. (2016). Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial. J. Gastroenterol. 52, 432-443. doi: 10.1007/s00535-016-1224-y
18. Hungin, A. P. S., Mulligan, C., Pot, B., Whorwell, P., Agréus, L., Fracasso, P., et al. (2013). Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice-an evidence-based international guide. Aliment. Pharmacol. Ther. 38, 864-886. doi: 10.1111/apt.12460
19. Jalankatuovinen, J., Salojärvi, J., Salonen, A., Immonen, O., Garsed, K., Kelly, F. M., et al. (2014). Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 63, 1737-1745. doi: 10.1136/gutjnl-2013-305994
20. Jeffery, I. B., O'Toole, P. W., öhman, L., Claesson, M. J., Deane, J., Quigley, E. M. M., et al. (2012). An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61, 997-1006. doi: 10.1136/gutjnl-2011-301501
21. Kang, N. L., and Lee, O. Y. (2014). Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J. Gastroenterol. 20, 8886-8897. doi: 10.3748/wjg.v20.i27.8886
22. Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., et al. (2007). The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133, 24-33. doi: 10.1053/j.gastro.2007.04.005
23. Kerckhoffs, A. P., Samsom, M., van der Rest, M. E., de Vogel, J., Knol, J., Ben-Amor, K., et al. (2009). Lower bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J. Gastroenterol. 15, 2887-2892. doi: 10.3748/wjg.15.2887
24. Kim, G., Deepinder, F., Morales, W., Hwang, L., Weitsman, S., Chang, C., et al. (2012). Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig. Dis. Sci. 57, 3213-3218. doi: 10.1007/s10620-012-2197-1
25. Kleessen, B., and Blaut, M. (2005). Modulation of gut mucosal biofilms. Br. J. Nutr. 93, S35-S40. doi: 10.1079/BJN20041346
26. Kleessen, B., Hartmann, L., and Blaut, M. (2003). Fructans in the diet cause alterations of intestinal mucosal architecture, released mucins and mucosa-associated bifidobacteria in gnotobiotic rats. Br. J. Nutr. 89, 597-606. doi: 10.1079/BJN2002827
27. Li, J., Lin, S., Vanhoutte, P. M., Woo, C. W., and Xu, A. (2016). Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe-/-mice. Circulation 133, 2434-2446. doi: 10.1161/CIRCULATIONAHA.115.019645
28. Li, Z., Henning, S., Lee, R., Lu, Q., Summanen, P., Thames, G., et al. (2015). Pomegranate extract induces ellagitannin metabolite formation and changes stool microbiota in healthy volunteers. Food Funct. 6, 2487-2495. doi: 10.1039/c5fo00669d
29. Malinen, E., Rinttilä, T., Kajander, K., Mättö, J., Kassinen, A., Krogius, L., et al. (2005). Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am. J. Gastroenterol. 100, 373-382. doi: 10.1111/j.1572-0241.2005.40312.x
30. Olesen, M., and Gudmand-Høyer, E. (2000). Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am. J. Clin. Nutr. 72, 1570-1575
31. Pasricha, P. J. (2007). Desperately seeking serotonin a commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 132, 2287-2290. doi: 10.1053/j.gastro.2007.04.057
32. Posserud, I., Stotzer, P. O., Björnsson, E. S., Abrahamsson, H., and Simrén, M. (2007). Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56, 802-808. doi: 10.1136/gut.2006.108712
33. Rajilic-Stojanovic, M., Biagi, E., Heilig, H. G., Kajander, K., Kekkonen, R. A., Tims, S., et al. (2011). Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141, 1792-1801. doi: 10.1053/j.gastro.2011.07.043
34. Rigsbee, L., Agans, R., Shankar, V., Kenche, H., Khamis, H. J., Michail, S., et al. (2012). Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 107, 1740-1751. doi: 10.1038/ajg.2012.287
35. Rinttilä, T., Lyra, A., Krogiuskurikka, L., and Palva, A. (2010). Real-time PCR analysis of enteric pathogens from fecal samples of irritable bowel syndrome subjects. Gut Pathog. 3:6. doi: 10.1186/1757-4749-3-6
36. Rivkin, A. (2003). Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review. Clin. Ther. 25, 1952-1974. doi: 10.1016/S0149-2918(03)80198-4
37. Roopchand, D. E., Carmody, R. N., Kuhn, P., Moskal, K., Rojassilva, P., Turnbaugh, P. J., et al. (2015). Dietary polyphenols promote growth of the gut bacterium Akkermansia muciniphila and attenuate gigh-fat diet-induced metabolic syndrome. Diabetes 64, 2847-2858. doi: 10.2337/db14-1916
38. Saulnier, D. M., Riehle, K., and Mistretta, T. A. (2011). Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141, 1782-1791. doi: 10.1053/j.gastro.2011.06.072
39. Spiller, R., and Garsed, K. (2009). Postinfectious irritable bowel syndrome. Gastroenterology 136, 1979-1988. doi: 10.1053/j.gastro.2009.02.074
40. Stark, D., Hal, S. V., Marriott, D., Ellis, J., and Harkness, J. (2007). Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis. Int. J. Parasitol. 37, 11-20. doi: 10.1016/j.ijpara.2006.09.009
41. Van der Sluis, M., De Koning, B. A., De Bruijn, A. C., Velcich, A., Meijerink, J. P., Van Goudoever, J. B., et al. (2006). Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131, 117-129. doi: 10.1053/j.gastro.2006.04.020
42. Wang, Y., Zhou, S., Wang, Y., Gong, Z., Yang, Q., Kan, X., et al. (2013). Influence of Wuji Wan in different compatibilities on colonic motility and 5-hydroxytryptamine contents in rats with post-infectious irritable bowel syndrome. World J. Gastroenterol. 21, 1226-1233. doi: 10.11569/wcjd.v21.i13.1226
43. Xu, J., Lian, F., Zhao, L., Zhao, Y., Chen, X., Zhang, X., et al. (2015). Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J. 9, 552-562. doi: 10.1038/ismej.2014.177
44. Zhang, C., and Zhao, L. (2016). Strain-level dissection of the contribution of the gut microbiome to human metabolic disease. Genome Med. 8:41. doi: 10.1186/s13073-016-0304-1
45. Zhang, X., Zhao, Y., Xu, J., Xue, Z., Zhang, M., Pang, X., et al. (2015). Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci. Rep. 5:14405. doi: 10.1038/srep14405
46. Zhang, Z., Wu, X., Cao, S., Wang, L., Wang, D., Yang, H., et al. (2016). Caffeic acid ameliorates colitis in association with increased Akkermansia population in the gut microbiota of mice. Oncotarget 7, 31790-31799. doi: 10.18632/oncotarget.9306
47. Zhou, Z. Y., Ren, L. W., Zhan, P., Yang, H. Y., Chai, D. D., and Yu, Z. W. (2016). Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling. Acta Pharmacol. Sin. 37, 1063-1075. doi: 10.1038/aps.2016.21